Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

R&E tax credits

Executive Summary

Plan to make permanent the current tax credits for research and experimentation expenditures is under consideration by the Senate Finance Committee for inclusion in the budget reconciliation package. The House passed a provision making the tax credit permanent on Oct. 5 in its Omnibus Budget Reconciliation bill, HR 3299. The House plan would restructure the tax credit by changing the definition of "spending base" by indexing it to individual company sales; the Finance Committee is considering a similar approach. The House also agreed to provide a permanent rule under which companies would allocate 64% of expenses for R&E conducted outside the U.S. to foreign source income.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS016362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel